Sanofi (SAN.PA)
| Previous close | 87.70 |
| Open | 87.68 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 87.63 - 91.66 |
| 52-week range | 80.60 - 104.90 |
| Volume | |
| Avg. volume | 1,365,420 |
| Market cap | 115.596B |
| Beta (5Y monthly) | 0.45 |
| PE ratio (TTM) | 21.26 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 3.76 (4.29%) |
| Ex-dividend date | 13 May 2024 |
| 1y target est | N/A |
- Investor's Business Daily
AstraZeneca, Sanofi Jump On First-Quarter Earnings; Bristol Myers Lags
AstraZeneca soundly topped analyst views while Sanofi narrowed its losses. Both stocks surged in early trade.
- Reuters
UPDATE 2-Sanofi profit slips on generic competition and currency effects
Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent, the French drugmaker said on Thursday. Operating income adjusted for one-offs slipped to 2.84 billion euros ($3.04 billion), a touch above the 2.79 billion euros expected by analysts in a poll on Sanofi's website. The company reiterated that it expects 2024 adjusted earnings per share (EPS) to slip by a low single-digit percentage, excluding currency swings, citing higher taxes and an increase in development expenditure.
- Reuters
Sanofi profit slips on generic competition and currency effects
(Reuters) -Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent, the French drugmaker said on Thursday. Operating income adjusted for one-offs slipped to 2.84 billion euros ($3.04 billion), a touch above the 2.79 billion euros expected by analysts in a poll on Sanofi's website. The company reiterated that it expects 2024 adjusted earnings per share (EPS) to slip by a low single-digit percentage, excluding currency swings, citing higher taxes and an increase in development expenditure.
